tbuckley/cabot-search huggingface dataset:
An injectable collagen-genipin-carbon dot hydrogel combined with photodynamic therapy to enhance chondrogenesis
Authors: Zhenhui Lu, Sijia Liu, Yiguan Le, Zainen Qin, Mingwei He, Fuben Xu, Ye Zhu, Jinmin Zhao, Chuanbin Mao, Li Zheng
Journal: Biomaterials (2019)
Frequent intra- and inter-species introgression shapes the landscape of genetic variation in bread wheat
Authors: Hong Cheng, Jing Liu, Jia Wen, Xiaojun Nie, Luohao Xu, Ningbo Chen, Zhongxing Li, Qilin Wang, Zhuqing Zheng, Ming Li, Licao Cui, Zihua Liu, Jianxin Bian, Zhonghua Wang, Shengbao Xu, Qin Yang, Rudi Appels, Dejun Han, Weining Song, Qixin Sun, Yu Jiang
Journal: Genome biology (2019)

Bread wheat is one of the most important and broadly studied crops. However, due to the complexity of its genome and incomplete genome collection of wild populations, the bread wheat genome landscape and domestication history remain elusive.By investigating the whole-genome resequencing data of 93 accessions from worldwide populations of bread wheat and its diploid and tetraploid progenitors, together with 90 published exome-capture data, we find that the B subgenome has more variations than A and D subgenomes, including SNPs and deletions. Population genetics analyses support a monophyletic origin of domesticated wheat from wild emmer in northern Levant, with substantial introgressed genomic fragments from southern Levant. Southern Levant contributes more than 676 Mb in AB subgenomes and enriched in the pericentromeric regions. The AB subgenome introgression happens at the early stage of wheat speciation and partially contributes to their greater genetic diversity. Furthermore, we detect massive alien introgressions that originated from distant species through natural and artificial hybridizations, resulting in the reintroduction of ~ 709 Mb and ~ 1577 Mb sequences into bread wheat landraces and varieties, respectively. A large fraction of these intra- and inter-introgression fragments are associated with quantitative trait loci of important traits, and selection events are also identified.We reveal the significance of multiple introgressions from distant wild populations and alien species in shaping the genetic components of bread wheat, and provide important resources and new perspectives for future wheat breeding.
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
Authors: Yunlu Jia, Wee-Joo Chng, Jianbiao Zhou
Journal: Journal of Hematology & Oncology (2019)

Super-enhancers (SEs) in a broad range of human cell types are large clusters of enhancers with aberrant high levels of transcription factor binding, which are central to drive expression of genes in controlling cell identity and stimulating oncogenic transcription. Cancer cells acquire super-enhancers at oncogene and cancerous phenotype relies on these abnormal transcription propelled by SEs. Furthermore, specific inhibitors targeting SEs assembly and activation have offered potential targets for treating various tumors including hematological malignancies. Here, we first review the identification, functional significance of SEs. Next, we summarize recent findings of SEs and SE-driven gene regulation in normal hematopoiesis and hematologic malignancies. The importance and various modes of SE-mediated MYC oncogene amplification are illustrated. Finally, we highlight the progress of SEs as selective therapeutic targets in basic research and clinical trials. Some open questions regarding functional significance and future directions of targeting SEs in the clinic will be discussed too.
Tumor-collagen digital proximity signature to indicate prognosis in diffuse large B-cell lymphoma.
Authors: Talha Qaiser, Matthew Pugh, Sandra Margielewska, Robert Hollows, Paul Murray, Nasir Rajpoot
Journal: Journal of Clinical Oncology (2019)

e19073 Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous tumor that originates from normal B-cells. Despite the use of combination chemotherapy, around 40% of DLBCL patients die (de Jonge, et al. European Journal of Cancer, 2016). Limited studies have investigated the role of collagen in the acellular tumor microenvironment. In this study, we present a novel digital signature of the proximity of tumor cells and collagen-VI (COL6) that can predict overall survival (OS) in DLBCL patients. To the best of our knowledge, this is the first study of its kind to employ automated image analysis. Methods: The proposed digital proximity signature (DPS) aggregates summary-level statistics from the entire whole slide image (WSI) and serves as a marker of regions, categorizing weak, moderate, significant, and strong tumor-collagen proximity and can be described as a surrogate for signaling. To accomplish this, we developed a novel artificial intelligence (AI) based multi-task model for simultaneous detection and classification of tumor cells and another bespoke method for automatically identifying COL6 fiber. The tumor-collagen proximity analysis was then performed by aggregating tumor cell statistics within the vicinity of COL6 fibres. Finally, the prognostic significance of DPS for OS in DLBCL was investigated with Kaplan-Meier analysis, stratifying patients into two groups based on the median of the DPS values. Results: We took WSIs of DLBCL tissue slides for 32 cases immunohistochemically stained with COL6 and Hematoxylin counterstain. The AI model for tumor cell identification achieved a high F1-score of 0.84, outperforming recent single-task learning models. Our results show that strong proximity of COL6 and tumor cells is linked to better OS in DLBCL patients ( p = 0.03). Conclusions: Our novel digitally computed COL6-tumor proximity signature shows prognostic significance for overall survival on a pilot dataset of 32 DLBCL patients. We are further validating the utility of this novel signature as a prognostic biomarker in larger cohorts of DLBCL patients.
Tailored combined treatment with radiofrequency ablation plus octreotide in advanced hepatocellular carcinoma
Authors: S. del Prete, R. Addeo, M. Caraglia, V. Faiola, R. Guarrasi, A. Palmeri, E. Capasso, V. Nocera, L. Tarantino
Journal: Journal of Clinical Oncology (2007)

15173 Background: Local therapies represent a valuable choice in small hepatocellular carcinoma (HCC), however, radiofrequency ablation (RFA) is increasingly used in advanced tumors. Medical treatments generally gave frustrating results in advanced hepatocellular carcinoma. Several biological non chemotherapeutic drugs are currently tested in HCC. Based on the expression of somatostatin receptor subtypes by HCC and the tolerability profile, octreotide was evaluated in single cases and small series of HCC patients and conflicting results are reported. Methods: 35 advanced HCC (26 males, 9 females; age range 55–85 years, median 73 years) were treated with RFA and octreotide with the aim to evaluate safety and determine the effect on disease control and survival. Testing regular and increasing doses of long-acting octreotide (from 20 to 30 mg monthly) were planned in the treatment schedule. Child A and Child B patients were 60% and about 34% of the cases, respectively. Only two patients with Child C compensated cirrhosis were included. All patients have multiple liver HCC nodules and one had bone metastases. Treatment with octreotide was maintained until disease progression or unacceptable toxicity. RFA was performed before or during treatment with octreotide according to medical evaluation. Results: In the majority of patients (65,7%) stable disease was obtained. In 3 patients (8,5%) progression of disease was documented. Clinical progression of underlying cirrhosis was identified in four patients and appear to condition the outcome, independently from HCC. Both medical and local treatments were well tolerated. Statistical evaluation was presented at ASCO 2007. Conclusions: The combined treatment with RFA and octreotide can be feasible in advanced HCC patients. No significant financial relationships to disclose.
Drug-Induced Liver Injury — Types and Phenotypes
Authors: Jay H. Hoofnagle, Einar S. Björnsson
Journal: New England Journal of Medicine (2019)

The liver has a range of responses to drug-induced injury, with a number of phenotypes. In addition, idiosyncratic reactions may occur as a consequence of both direct drug action and indirect drug effects. Antibiotics are the most common cause of drug-induced liver injury.
Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy
Authors: Francis Yi Xing Lai, Eleanor Higgins, Catherine H. Smith, Jonathan N. Barker, Andrew Pink
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial
Authors: Marla J Keller, Lianna Wood, James M Billingsley, Laurie L Ray, Jessica Goymer, Shada Sinclair, Aileen P McGinn, Mark A Marzinke, Bruce Frank, Sujatha Srinivasan, Congzhou Liu, Jessica M Atrio, Lilia Espinoza, Nelly Mugo, Hans M L Spiegel, Peter L Anderson, David N Fredricks, Craig W Hendrix, Jeanne Marrazzo, Steven E Bosinger, Betsy C Herold
Journal: The Lancet HIV (2019)
Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study
Authors: Sonia Moretti, Edoardo Alesse, Luisa Di Marzio, Francesca Zazzeroni, Barbara Ruggeri, Sonia Marcellini, Giuseppe Famularo, Seth M. Steinberg, Antonio Boschini, M. Grazia Cifone, Claudio De Simone
Journal: Blood (1998)
Identification of a Spinal Circuit for Mechanical and Persistent Spontaneous Itch
Authors: Haili Pan, Mahar Fatima, Alan Li, Hankyu Lee, Wei Cai, Lorraine Horwitz, Chia Chun Hor, Nizam Zaher, Mitchell Cin, Hannah Slade, Tianwen Huang, X.Z. Shawn Xu, Bo Duan
Journal: Neuron (2019)
18F-FDG PET/CT in Oral Cuniculatum Carcinoma
Authors: Sebastien Dejust, Khadija El Farsaoui, Sara Bellefqih, Paul Lalire, David Morland
Journal: Clinical Nuclear Medicine (2019)

Abstract A 69-year-old woman was referred for initial staging of an oral cavity mass. 18 F-FDG PET/CT displayed a homogeneous intense uptake of the 50-mm left hemipalatal mass with local extension to the dental arcade and maxillary sinus. Infracentimetric bilateral cervical nodes with faint uptake were also detected, contrasting with the usual presentation of other head and neck squamous cell carcinoma. Biopsy concluded to a rare head and neck squamous cell carcinoma subtype: oral cuniculatum carcinoma (OCC). After radiotherapy, 18F-FDG PET/CT showed metabolic complete response. Our case describing specifically the metabolic characteristics of OCC and radiotherapy evaluation for this rare tumor.
Managing immune-related adverse events (irAEs): A new educational resource for health care professionals (HCPs) and patients.
Authors: Laura S. Wood, Brianna Hoffner, Krista M. Rubin, Marianne Davies, Lisa A. Tushla, Valerie Guild, Samantha R. Guild
Journal: Journal of Clinical Oncology (2019)

75 Background: Immune checkpoint inhibitors (ICIs) have changed treatment options for many cancer patients. Educating HCPs, patients, and caregivers is crucial to early identification of irAEs, ensuring prompt intervention and improved outcomes. Resources for oncology HCPs are scattered, including published articles, websites, and pharmaceutical materials. These resources are restricted to information from the package insert and limited in the scope of guidance provided. Methods: Melanoma advance practice providers (APPs) collaborated with the AIM at Melanoma Foundation and Terranova Medica in 2016 to create the Melanoma Nurse Initiative, featuring educational information regarding immunotherapy and irAE management. Based on website success (&gt;9200 professional interactions), learner survey data, and continued expansion of agents and indications, the need for a more expansive resource was identified. Results: AIM With Immunotherapy ( www.aimwithimmunotherapy.org/ ) launched in October 2018. Resources were developed by APPs with extensive experience with immunotherapy, education, and irAE management. Care Step Pathways provide comprehensive information on assessment, toxicity grading, and management. The HCP Toolkits include printable pages on drug information, side effect management, clinical pearls, and resources. Patient Action Plans, individualizable for each patient, include many detailed irAE information sheets. Videos for both HCPs and patients as well as a community Q/A panel provide additional multimedia, interactive resources. Learner surveys are planned to gauge how the content is used in the clinic setting and remaining unmet educational needs. Conclusions: Knowledge regarding immunotherapy, irAEs, and management of toxicities unique to immunotherapy is critical to maximizing clinical outcomes and quality of life for patients and their caregivers. AIM With Immunotherapy is a new website developed by expert oncology practitioners that provides comprehensive non-branded HCP resources and printable information to facilitate effective education of patients receiving immunotherapy.
Allergenomics of the tick <i>Ixodes ricinus</i> reveals important α‐Gal–carrying IgE‐binding proteins in red meat allergy
Authors: Danijela Apostolovic, Jelena Mihailovic, Scott P. Commins, Michiel Wijnveld, Maria Kazimirova, Maria Starkhammar, Hannes Stockinger, Thomas A. E. Platts‐Mills, Tanja Cirkovic Velickovic, Carl Hamsten, Marianne van Hage
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Nivolumab treatment in advanced non-small cell lung cancer (NSCLC): Retrospective analysis of real-life data in the Hospital Universitario Reina Sofía (HURS).
Authors: Carmen GarcÃa DurÃ¡n, Alberto L. Moreno-Vega, Pedro Sánchez Mauriño, Javier López-González, Isidoro C. Barneto - Aranda, Juan De La Haba, Enrique Aranda Aguilar
Journal: Journal of Clinical Oncology (2019)

108 Background: Recently, nivolumab has been approval as 2nd-line treatment of non-small cell lung cancer (NSCLC) in our country. Data regarding its effectiveness or safety in real-life setting are publishing daily. Methods: 27 patients with advanced NSCLC treated with nivolumab at HURS between February 2016 to November 2017, were evaluated for survival (overall survival OS, progression-free survival PFS), time to treatment failure (TTF), treatment discontinuation due to toxicity and demographics/clinicopathological characteristics, using SPSS v 8.0. Results: Median age was 62 years; 77,8% males. At closing data, 25,9% of patients were still receiving nivolumab treatment. 51,9 % had finished treatment due to disease progression and 7,4% to toxicity. 25,9% patients continued others chemotherapies schedules. Mean of cycles received was 11. 51,8% presented ORR to nivolumab (78% PR). The median TTF at nivolumab was 3 months. The median progression-free survival (PFS) was 6.93 months (6,2 months in the squamous histology vs 9,42 in adenocarcinoma). The median OS was 22.6 months. Neutrophil-lymphocyte ratio in a complete blood count did not decrease during nivolumab treatment in any patients (p &lt; 0.05, McNemar test), no relation to survival rates (with a cut-off of 5 and 3). Conclusions: Effectiveness (OS and PFS) of nivoumab were high in our patients, slightly better than those observed with similar characteristics included in clinical trials. We have not found predictive survival markers.
Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.
Authors: Matthew Joshua Frank, Nasheed M. Hossain, Ali Abbas Bukhari, Erin Dean, Jay Y. Spiegel, Gursharan K. Claire, Ilan Kirsch, Allison Jacob, Chelsea D. Mullins, Lik Wee Lee, Katherine A. Kong, Juliana K. Craig, Crystal Mackall, Aaron Rapoport, Saurabh Dahiya, Frederick Lundry Locke, David Bernard Miklos
Journal: Journal of Clinical Oncology (2019)

7552 Background: Axicabtagene Ciloleucel (Axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Long‐term analysis of the Zuma‐1 clinical trial showed ~40% of patients remained progression-free at 2 years (Locke, Lancet Oncology 2018). Early identification of patients who will later progress after CAR T cell therapy may improve clinical care and patient outcomes. Methods: As of 2/1/2019, we enrolled 50 patients on a multi-institutional, prospective study measuring circulating tumor DNA(ctDNA) minimal residual disease (MRD) in r/r DLBCL patients undergoing treatment with Axi-cel. Using an next generation sequencing-MRD assay (Adaptive Biotechnologies; Seattle WA), ctDNA levels were measured pre, 0, 7, 14, 21, 28, 56, 90, 180, 270, and 365 days following Axi-cel infusion. A pre-planned comparison between EDTA, Streck, and CFD tubes for the initial 10 enrolled patients determined the CFD tube provided optimal analyte stability over 144 hours following sample collection. CFD tubes are being used to collect all study samples. Results: 24 subjects have 3 or more months clinical follow up and their treatment ctDNA MRD significantly associated with clinical outcomes. A day 28 landmark analysis shows 12 patients were MRD negative and 12 patients were MRD positive as defined by detection of none or any tumor-associated ctDNA, respectively. 10 of 12 MRD+ patients subsequently developed progressive disease. In contrast, only 2 MRD- patients subsequently progressed and the 10 other patients remain in a CR. (p = 0.0033, Fisher's exact test). With a median follow up of 237 days, median PFS after Axi-cel infusion for day 28 MRD+ vs. MRD- patients is 93 days vs. not reach, p = 0.0010 by Log-rank test. Median OS for day 28 MRD+ vs. MRD- patients is 281 days after Axi-cel infusion vs. not reach, p = 0.0399 by Log-rank test. Conclusions: After Axi-cel infusion, day 28 ctDNA-based MRD significantly associates with PFS and OS and identified early at-risk patients prior to progression. These results provide a rationale for designing MRD-based risk-adaptive CAR T-cell clinical trials.
Quality and Safety in Healthcare, Part LV
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2019)

Abstract Leadership is very important to reduce burnout and promote happiness in the healthcare workplace. Whereas burnout and unhappiness lead to doctor turnover, more errors, more accidents, and decreased patient satisfaction, joy in the workplace results in better patient care, enhanced engagement and productivity, and more profitability for the healthcare organization. Many leadership characteristics are critical including integrity, putting the well-being of others first, being fair, standing for important principles, being a good role model, being an excellent communicator, encouraging new ideas and adopting them when feasible, and loving people.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Authors: Franck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, Pascale Cony-Makhoul, Aude Charbonnier, Martine Escoffre-Barbe, Françoise Rigal-Huguet, Valérie Coiteux, Bruno Varet, Viviane Dubruille, Pascal Lenain, Philippe Rousselot, Delphine Rea, Agnès Guerci-Bresler, Laurence Legros, Jixing Liu, Martine Gardembas, Jean-Christophe Ianotto, Pascal Turlure, Hyacinthe Johnson-Ansah, Juliana Martiniuc, Henry Jardel, Bertrand Joly, Patricia Zunic, Tawfiq Henni, Bruno Villemagne, Marc G. Berger, Emilie Cayssials, François Guilhot, Fabrice Larosa, Joëlle Guilhot, Gabriel Etienne, François-Xavier Mahon
Journal: Clinical Cancer Research (2019)

Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic myelogenous leukemia (CML) management and several studies have demonstrated the feasibility of safely stopping imatinib. A sustained deep molecular response on long-term TKI is critical prior to attempting treatment-free remission. Reproducible results from several studies reported recently, failed to identify robust and reproducible predictive factors for the selection of the best candidates for successful TKI cessation.We conducted a prospective national phase II study evaluating the cessation of imatinib after at least 2 years of MR4.5 obtained on imatinib first-line in patients with chronic phase CML.A total of 218 patients with de novo chronic phase CML were involved in the study. The median follow-up after imatinib cessation was 23.5 (1-64) months, 2 patients died from unrelated causes, and 107 experienced a confirmed increase in BCR-ABL1 levels defined as molecular recurrence. The molecular recurrence-free survival was 52% [95% confidence interval (CI), 45%-59%] at 6 months, and 50% (95% CI, 43%-57%) at 24 months. Droplet digital PCR (ddPCR) was used to evaluate more accurately low levels of BCR-ABL1 in 175 of 218 patients at imatinib cessation. To apply positive BCR-ABL1/ABL1 ratios on the international scale (IS), a conversion factor was calculated for ddPCR and the significant cut-off point was established at 0.0023%IS. In a multivariate analysis, the duration of TKI (≥74.8 months) and ddPCR (≥0.0023%IS) were the two identified predictive factors of molecular recurrence, with P = 0.0366 (HR, 0.635; 95% CI, 0.415-0.972] and P = 0.008 (HR, 0.556; 95% CI, 0.360-0.858), respectively.We conclude that the duration of TKI and residual leukemic cell load as determined by ddPCR are key factors for predicting successful treatment-free remission for patients with de novo chronic phase CML.See related commentary by Yan et al., p. 6561.
Matching burden of skin diseases, demand for dermatological consultations and clinical research activity: results from three national studies
Authors: E. Gutiérrez‐González, M.A. Descalzo, A. Molina‐Leyva, T. Kueder‐Pajares, A. Buendía‐Eisman, I. García‐Doval
Journal: British Journal of Dermatology (2019)